An observational study in Liver Cancer, Microbiota and Adverse Event, sponsored by First Affiliated Hospital of Wenzhou Medical University. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-09-13.
Sponsored by First Affiliated Hospital of Wenzhou Medical University · Observational
By tracking the short-term and long-term results of HCC patients treated with systemic therapies,the difference of microbiota between responded patients and non-responded patients was analyzed, and the correlation between gut and oral microbiota and short-term and long-term results was explored, so as to improve people's awareness of microbiota and pay attention to its prevention and treatment.
The investigators consecutively admit patients the questionnaire and collect the fecal. And by tracking the short-term and long-term outcomes of HCC patients treated with systemic therapies,the difference of gut microbiota between responded patients and non-responded patients is analyzed, and the correlation between gut and oral microbiota and short-term and long-term results is explored.Adverse events (AE) are recorded using the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 4.0).Tumor response is mainly evaluated by experienced hepatologists using radiological method within 4-12 weeks after treatments according to the RECIST 1.1 and Modified Response Evaluation Criteria in Solid Tumors (mRECIST).Overall survival (OS) and Progression-free survival (PFS) are recorded.
1,391 studies on the registry are indexed under Liver Neoplasms; 345 are open to participants now.
This study's planned enrollment of 200 is close to the median of 200 across 350 observational studies indexed under Liver Neoplasms.
Browse Liver Neoplasms studies →First Affiliated Hospital of Wenzhou Medical University is the lead sponsor of 82 studies on the registry; 56 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients with unresectable HCC who received systemic therapies
Exclusion Criteria:
Diagnostic Test: questionnaire survey
Diagnostic Test: questionnaire survey
All patients received lifestyle questionnaire, physical performance, and imaging evaluation before treatment.
Post-treatment adverse events
Post-treatment complications are recorded
Time frame: 3 months
Long-term outcomes after treatment
Overall survival and progression-free survival
Time frame: 1 year
Objective response rate
Tumor response
Time frame: 3 months
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital of Wenzhou Medical University